1. Introduction {#sec1-diagnostics-10-00460}
===============

Thymic epithelial tumors (TETs), which originate from thymic epithelial cells, include thymoma (TM), thymic carcinoma (TC), and thymic neuroendocrine tumors \[[@B1-diagnostics-10-00460],[@B2-diagnostics-10-00460]\]. These TETs have different biological functions, histological findings, and genomic profiles \[[@B2-diagnostics-10-00460],[@B3-diagnostics-10-00460]\]. TMs can be classified into type A, AB, B1, B2, B3, and C (TC) based on the World Health Organization (WHO) classification \[[@B1-diagnostics-10-00460]\]. According to the WHO classification, TETs, regardless of subtype or histology, are classified as malignant tumors \[[@B1-diagnostics-10-00460],[@B4-diagnostics-10-00460]\]. The incidence of TC is approximately 22% \[[@B5-diagnostics-10-00460]\], with squamous cell carcinoma being the most common subtype of TC, accounting for approximately 70% of all TCs \[[@B1-diagnostics-10-00460],[@B6-diagnostics-10-00460]\]; accurate differentiation between thymic squamous cell carcinoma and TM type B3 is required \[[@B1-diagnostics-10-00460]\]. Further, focal squamous differentiation and keratinization can be found in other types of TC, such as lymphoepithelioma-like carcinoma and basaloid carcinoma \[[@B1-diagnostics-10-00460]\]. In the diagnosis of anterior mediastinal tumors, the direct invasion and metastasis of pulmonary squamous cell carcinoma are required to differentiate between these tumors and TC. The pathologic diagnosis of an anterior mediastinal tumor is essential when determining treatment modality and prognosis \[[@B2-diagnostics-10-00460]\]. TC patients generally show a higher stage and worse prognosis compared to TM patients \[[@B3-diagnostics-10-00460],[@B7-diagnostics-10-00460]\], but the differential diagnosis is challenging when the given specimen is a small biopsied tissue. Previous studies reported the diagnostic implications of various immunohistochemical (IHC) markers, including CD117, a marker closely related to the invasion and metastasis of tumor cells, which is highly expressed in TC \[[@B2-diagnostics-10-00460]\]. In addition, Nakagawa et al. reported that the combination of CD117 and CD5 was useful for differentiating between thymic and lung squamous cell carcinoma \[[@B8-diagnostics-10-00460]\]. Insulin-like growth factor-1 receptor (IGF-1R) was proposed as a potential therapeutic target for TET and is more frequently expressed in TC than in TM \[[@B9-diagnostics-10-00460],[@B10-diagnostics-10-00460],[@B11-diagnostics-10-00460]\].

Although various IHC expressions were reported, single specific markers for each TET are not available. In our study, we evaluated the IHC expression patterns of TCs and TMs, alongside the performance of a diagnostic test accuracy review for various IHC markers.

2. Materials and Methods {#sec2-diagnostics-10-00460}
========================

2.1. Published Study Search and Selection Criteria {#sec2dot1-diagnostics-10-00460}
--------------------------------------------------

Relevant articles were obtained by searching the PubMed database through 31 January 2020. For searching, the keywords used were as follows: "thymic carcinoma or thymoma" and "immunohistochemistry". The titles and abstracts of all searched articles were screened for inclusion and exclusion. Included articles had the information for the immunohistochemistry of the TC and TM. However, case reports, non-original articles, or those written in English were excluded from the present study. The PRISMA checklist shown in the [supplementary Table S1](#app1-diagnostics-10-00460){ref-type="app"}.

2.2. Data Extraction {#sec2dot2-diagnostics-10-00460}
--------------------

Data associated with various IHC expressions of TC and TM were extracted from each of the eligible studies \[[@B2-diagnostics-10-00460],[@B8-diagnostics-10-00460],[@B9-diagnostics-10-00460],[@B10-diagnostics-10-00460],[@B11-diagnostics-10-00460],[@B12-diagnostics-10-00460],[@B13-diagnostics-10-00460],[@B14-diagnostics-10-00460],[@B15-diagnostics-10-00460],[@B16-diagnostics-10-00460],[@B17-diagnostics-10-00460],[@B18-diagnostics-10-00460],[@B19-diagnostics-10-00460],[@B20-diagnostics-10-00460],[@B21-diagnostics-10-00460],[@B22-diagnostics-10-00460],[@B23-diagnostics-10-00460],[@B24-diagnostics-10-00460],[@B25-diagnostics-10-00460],[@B26-diagnostics-10-00460],[@B27-diagnostics-10-00460],[@B28-diagnostics-10-00460],[@B29-diagnostics-10-00460],[@B30-diagnostics-10-00460],[@B31-diagnostics-10-00460],[@B32-diagnostics-10-00460],[@B33-diagnostics-10-00460],[@B34-diagnostics-10-00460],[@B35-diagnostics-10-00460],[@B36-diagnostics-10-00460],[@B37-diagnostics-10-00460],[@B38-diagnostics-10-00460],[@B39-diagnostics-10-00460],[@B40-diagnostics-10-00460],[@B41-diagnostics-10-00460],[@B42-diagnostics-10-00460],[@B43-diagnostics-10-00460],[@B44-diagnostics-10-00460]\]. Two independent authors extracted all of the data. Extracted data were the author's information, study location, number of patients analyzed, and tumor subtypes of TM. In addition, the expression rates by IHC markers were investigated in TC and TM.

2.3. Statistical Analyses {#sec2dot3-diagnostics-10-00460}
-------------------------

A meta-analysis was performed using the Comprehensive Meta-Analysis software 2.0 package (Biostat, Englewood, NJ, USA). The expression rates of various IHC markers were investigated by dividing them into TC and TM markers. Comparisons of IHC expressions between TC and TM type B3 were also performed. Heterogeneity between the studies was checked using *Q* and *I^2^* statistics and expressed as *p*-values. Additionally, sensitivity analysis was conducted to assess the heterogeneity of eligible studies and the impact of each study on the combined effects. Due to the use of various evaluation criteria and tumor types in the eligible studies, a random-effect model rather than a fixed-effect model was determined to be more suitable for this meta-analysis. The Begg's funnel plot and Egger's test were performed to assess publication bias, with fail-safe N and trim-fill tests additionally used to confirm the degree of publication bias if found. The results were considered statistically significant at *p* \< 0.05. The diagnostic test accuracy review of various IHC markers was performed using R software ver. 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). We calculated the pooled sensitivity, specificity and diagnostic odds ratio (OR) according to individual data collected from each eligible study. By plotting the sensitivity and 1-specificity of each study, the summary receiver operating characteristic curve (SROC) was able to be constructed with curve fitting performed via linear regression. Due to all of the data being heterogeneous, accuracy data were pooled by fitting the SROC and measuring the area under the curve (AUC).

3. Results {#sec3-diagnostics-10-00460}
==========

3.1. Selection and Characteristics of the Studies {#sec3dot1-diagnostics-10-00460}
-------------------------------------------------

In this study, 934 relevant articles were searched for on the PubMed database and reviewed for a meta-analysis. Of these, 409 articles had no or lack of sufficient information for a meta-analysis. In addition, 267 were excluded due to non-original articles. Among the remaining articles, 220 reports were excluded for the following reasons: articles in other diseases (*n* = 105), non-human studies (*n* = 81), and a language other than English (*n* = 34) ([Figure 1](#diagnostics-10-00460-f001){ref-type="fig"}). Finally, 38 eligible articles were selected and included for the meta-analysis ([Table 1](#diagnostics-10-00460-t001){ref-type="table"}). These studies included 2497 patients, including TC (*n* = 636) and TM (*n* = 1861).

3.2. Comparison of Immunohistochemical Expressions between Thymic Carcinoma and Thymoma {#sec3dot2-diagnostics-10-00460}
---------------------------------------------------------------------------------------

First, the significant differences in IHC expressions between TC and TM were investigated. There were significant differences in immunohistochemistry for beta-5t, B-cell lymphoma 2 (Bcl-2), calretinin, CD1a, CD5, carcinoembryonic antigen (CEA), cytokeratin19 (CK19), CD117, Glut-1, IGF-1R, mesothelin, MOC31, MUC1, p21, and TdT ([Table 2](#diagnostics-10-00460-t002){ref-type="table"}). Among these markers, Bcl-2, calretinin, CD5, CEA, CD117, glucose transporter 1 (Glut-1), insulin-like growth factor 1 receptor (IGF-1R), mesothelin, MOC31, mucin1 (MUC1), and p21 showed significantly higher expressions in TC than in TM. On the other hand, TMs have shown higher expressions of beta-5t, CD1a, CK19, and terminal deoxynucleotidyl transferase (TdT) than TC. In comparison with TC, the significant differences in IHC expressions for beta-catenin and CD205 were found in TM type B3, but not in overall TM. Among markers with a significant difference, the estimated expression rates of CD205 were 0.650 (95% CI 0.461--0.801) and 0.958 (95% CI 0.757--0.994) in TC and TM type B3, respectively ([Table 3](#diagnostics-10-00460-t003){ref-type="table"}). In addition, the estimated expression rates of Glut-1 and IGF-1R were significantly higher in TC than in TM type B3. However, the Glut-1 and IGF-1R expression rates of TM type B3 were 52.6% and 64.6%, respectively.

3.3. Diagnostic Test Accuracy Review for Immunohistochemical Markers {#sec3dot3-diagnostics-10-00460}
--------------------------------------------------------------------

The diagnostic test accuracy reviews were performed for candidates of IHC markers, which were showed the statistical differences between TC and TM type B3. Five positive markers, including CD5, CD117, Glut-1, and IGF-1R, MUC1, and four negative markers, including beta-5t, CD1a, CD205, and TdT, were included in the present analysis ([Table 4](#diagnostics-10-00460-t004){ref-type="table"}). Among these markers, the most effective positive and negative markers may be MUC1 and beta-5t, 0.932 (95% CI 0.686--0.988), 0.847 (95% CI 0.505--0.968), 46.251 ( 95% CI 11.634--183.877), 0.921 and 1.000 ( 95% CI 0.927--1.000), 1.000 (95% CI 0.942--1.000), 571.396 (95% CI 33.356--9788.053), 0.985), in sensitivity, specificity, diagnostic OR, and AUC on SROC, respectively; [Table 4](#diagnostics-10-00460-t004){ref-type="table"}. The orders of AUC on SROC were MUC1, Glut-1, CD117, IGF-1R, and CD5 in positive markers and were beta-5t, TdT, CD1a, and CD205 in negative markers.

4. Discussion {#sec4-diagnostics-10-00460}
=============

Although the prognosis of each subtype of TETs is not clear, the prognosis of Type B3 TMs is clearly different from other subtypes of TMs and TC \[[@B22-diagnostics-10-00460],[@B45-diagnostics-10-00460],[@B46-diagnostics-10-00460]\]; however, histological similarities are often found in thymic squamous cell carcinoma and TM type B3 \[[@B4-diagnostics-10-00460],[@B22-diagnostics-10-00460],[@B45-diagnostics-10-00460]\]. Due to the potential importance of differentiation between TC and TM type B3, various IHC markers, such as CD117 and CD5, were introduced and studied \[[@B1-diagnostics-10-00460],[@B4-diagnostics-10-00460],[@B8-diagnostics-10-00460],[@B12-diagnostics-10-00460],[@B30-diagnostics-10-00460],[@B47-diagnostics-10-00460],[@B48-diagnostics-10-00460]\]. However, the accuracy of using these markers as a diagnostic test was not clarified \[[@B22-diagnostics-10-00460],[@B45-diagnostics-10-00460],[@B46-diagnostics-10-00460]\]. This study presented the first meta-analysis and diagnostic test accuracy review of the diagnostic roles of various IHC markers in TETs, including TC and TM.

TETs can be differentiated by histological characteristics \[[@B1-diagnostics-10-00460]\]; however, similar histologic findings are present between the subtypes of TET. Because each subtype exhibits different clinical behaviors and outcomes, a precise diagnosis is essential \[[@B14-diagnostics-10-00460],[@B49-diagnostics-10-00460]\]. The treatment of choice for TETs is surgical resection, where possible \[[@B50-diagnostics-10-00460]\]. In inoperable cases, the preoperative diagnosis may be more important in regard to treatment decisions, such as chemotherapy \[[@B51-diagnostics-10-00460]\]. However, other malignant and benign tumors can also occur in the thymus. The diagnostic goals for biopsy specimens could lie in defining malignant or benign tumors and differentiating between TETs and others. However, specimens obtained via needle biopsy have some limitations in regard to histological diagnosis. Immunohistochemistry is useful for the diagnosis of small biopsied specimens. In addition, information regarding various protein expression patterns is useful in regard to understanding tumorigenesis and developing targeted drugs.

Various tumors can occur in the anterior mediastinum, including TETs, germ cell tumors, and metastatic tumors. Differentiating between TET subtypes can be useful when deciding on treatments and predicting prognoses. Due to the similar histological findings of TC and TM type B3, diagnoses from small biopsied specimens are challenging in daily practice. However, single and specific IHC markers for each tumor are not yet defined. Specific markers have high expression in the target and low expression in the reference. According to our results, positive markers may be suitable for CD5, CD117, MUC1, and Glut-1 in differentiating TC from TM type B3. On the other hand, beta-5t, CD1a, and TdT are considered to be negative markers. In this study, we initially evaluated the statistical differences between TC and TM using odds ratios. In addition, we analyzed the expression rates of each IHC marker with statistical significance between TC and TM. These results should be considered before applying diagnostic markers in daily practice. Diagnostic implications, regardless of the statistical significance, are limited when IHC expression rates are high in both compared subgroups. Therefore, our results showed that the estimated expression rates were useful for the selection of an IHC panel.

Kim et al. suggested that an IHC panel using EZH2, CD117, and CD205 was useful for differentiation between TC and TM type B3 \[[@B46-diagnostics-10-00460]\]. In the previous study, EZH2 showed higher sensitivity (88.9%) and specificity (100%) in differentiating between TC and TM type B3 \[[@B46-diagnostics-10-00460]\]. However, because the raw data for EZH2 immunohistochemistry were not shown, the present study could not analyze these results. Based on our results, CD205 exhibited significantly lower expression in TC than in TM type B3. However, the CD205 expression rates of TC and TM type B3 were 65.0% and 95.8%, respectively. This difference in expression rate was not useful for differentiation between two tumor groups; further, information regarding negative markers was not shown \[[@B46-diagnostics-10-00460]\]. Some markers, such as beta-5t, CD1a, and TdT, showed higher expressions in TM type B3 than in TC, which may present negative marker candidates for TC. Therefore, an IHC panel using positive and negative markers could be useful for the diagnosis of TC and TM, and an IHC panel consisting of positive and negative markers for the diagnosis of an anterior mediastinal mass is recommended. This diagnostic test accuracy review was performed for IHC markers with significant differences in expression between TC and TM type B3. Positive markers included CD5, CD117, Glut-1, IGF-1R, MUC1 for TC, beta-5t, CD1a, CD205, and TdT for TM type B3. Markers with high sensitivity, specificity, and diagnostic odds ratios were considered to be more effective. Among the markers highly expressed in TC, Glut-1 showed the highest expression rate, 95.2%. However, in TM type B3, the expression rate of Glut-1 was 52.6% (95% CI 29.6--74.5%). In the diagnostic test accuracy review, Glut-1 showed the highest diagnostic odds ratio (46.251, 95% CI 11.634--183.877). MUC1 expression in TM type B3 ranged from 0% to 77.8% \[[@B13-diagnostics-10-00460],[@B21-diagnostics-10-00460],[@B36-diagnostics-10-00460]\], indicating a limited diagnostic role of MUC1, as well as Glut-1. Based on these criteria, the important markers were shown to be CD5 and CD117 (positive) and TdT and beta-5t (negative) for TCs.

The direct invasion and metastasis of primary lung cancers in the anterior mediastinum can be detected \[[@B1-diagnostics-10-00460]\]. Based on the histological findings, it is difficult to differentiate between lung and thymic squamous cell carcinomas. Among the markers expressed in TC, CD5, CD117, and CD205 are uncommonly expressed in primary lung cancers \[[@B8-diagnostics-10-00460]\], thereby presenting these markers as possible candidates in the IHC panel of thymic tumors when differentiating primary lung cancers. According to our results, CD205 may be comparable in differentiation from tumors of lung origin because it is expressed in both TC and TM. In addition, CD205 is useful for defining thymic origin. Taken together, an IHC panel containing CD205 as a positive and a negative marker would be more effective.

This study has a limitation in that we performed the diagnostic test accuracy review for individual IHC markers, but it was difficult to conduct the diagnostic test accuracy review for a combination of markers due to limited eligible study information. Therefore, the recommended IHC panels could not clarify the diagnostic role of the differentiation of thymic masses.

5. Conclusions {#sec5-diagnostics-10-00460}
==============

In conclusion, our results showed that significant differences in IHC expression between TC and TM identified positive markers, including CD5, CD117, Glut-1, IGF-1R, and MUC1, and negative markers, including beta-5t, CD1a, CD205, and TdT against TC. An IHC panel including positive and negative markers, as well as CD205, could be useful to differentiate between thymic masses in daily practice.

The following are available online at <https://www.mdpi.com/2075-4418/10/7/460/s1>, Table S1. PRISMA Checklist.
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diagnostics-10-00460-t001_Table 1

###### 

Main characteristics of the eligible studies.

  Study                                                         Location   Number of Patients                             
  ------------------------------------------------------------- ---------- -------------------- ----- ---- ---- ---- ---- ----
  Adam 2014 \[[@B9-diagnostics-10-00460]\]                      Germany    24                   45                        
  Chen 1996 \[[@B10-diagnostics-10-00460]\]                     Taiwan     26                   15                        
  Cui 2011 \[[@B11-diagnostics-10-00460]\]                      China      4                    39    2    5    7    14   11
  Dorfman 1997 \[[@B12-diagnostics-10-00460]\]                  USA        24                   41                        
  Du 2016 \[[@B13-diagnostics-10-00460]\]                       China      22                   21                        21
  Girard 2009 \[[@B14-diagnostics-10-00460]\]                   USA        7                    38    8              22   8
  Girard 2010 \[[@B15-diagnostics-10-00460]\]                   USA        7                    56    5    12   8    21   10
  Hayashi 2013 \[[@B16-diagnostics-10-00460]\]                  Japan      18                   17                        17
  Henley 2002 \[[@B17-diagnostics-10-00460]\]                   USA        6                    36                        
  Hino 1997 \[[@B18-diagnostics-10-00460]\]                     Japan      19                   17                        
  Hirabayashi 1997 \[[@B19-diagnostics-10-00460]\]              Japan      4                    36                        
  Hiroshima 2002 \[[@B20-diagnostics-10-00460]\]                Japan      10                   36    8    8    7    7    6
  Kaira 2011 \[[@B21-diagnostics-10-00460]\]                    Japan      17                   5                         5
  Khoury 2010 \[[@B22-diagnostics-10-00460]\]                   USA        12                   54                        17
  Kornstein 1997 \[[@B23-diagnostics-10-00460]\]                USA        24                   85                        
  Laury 2011 \[[@B24-diagnostics-10-00460]\]                    USA        5                    9                         
  Lee 2019 \[[@B25-diagnostics-10-00460]\]                      Korea      30                   110   11   31   28   16   19
  Mimae 2011 \[[@B26-diagnostics-10-00460]\]                    Japan      37                   103                       6
  Mimae 2012 \[[@B27-diagnostics-10-00460]\]                    USA        37                   103                       6
  Nakagawa 2005 \[[@B8-diagnostics-10-00460]\]                  Japan      20                   50    10   10   10   10   10
  Nonaka 2007 \[[@B28-diagnostics-10-00460]\]                   USA        16                   58    9    19   7    16   7
  Omatsu 2012 \[[@B29-diagnostics-10-00460]\]                   Japan      22                   22    1    1    7    7    6
  Pan 2003 \[[@B30-diagnostics-10-00460]\]                      Taiwan     22                   35    9    10   4    7    5
  Petrini 2010 \[[@B31-diagnostics-10-00460]\]                  Italy      13                   105                       
  Remon 2017 \[[@B32-diagnostics-10-00460]\]                    France     12                   84    4    25   8    27   20
  Rieker 2006 \[[@B33-diagnostics-10-00460]\]                   Germany    4                    30    8    6    5    6    5
  Song 2012 \[[@B34-diagnostics-10-00460]\]                     China      15                   87    3    29   5    22   28
  Stefanaki 1997 \[[@B35-diagnostics-10-00460]\]                Greece     2                    29                        
  Su 2015 \[[@B36-diagnostics-10-00460]\]                       China      20                   16                        16
  Suzuki 2018 \[[@B37-diagnostics-10-00460]\]                   Japan      10                   7                         
  Tateyama 1999 \[[@B38-diagnostics-10-00460]\]                 Japan      7                    18                        
  Thomas 2016 \[[@B39-diagnostics-10-00460]\]                   USA        34                   29                        
  Thomas de Montpréville 2015 \[[@B40-diagnostics-10-00460]\]   France     16                   75    5    17   11   25   17
  Tsuchida 2008 \[[@B41-diagnostics-10-00460]\]                 Japan      17                   20         5    4    6    5
  Weissferdt 2011 \[[@B42-diagnostics-10-00460]\]               USA        31                   60    30                  
  Wu 2019 \[[@B2-diagnostics-10-00460]\]                        China      22                   128   11   35   19   40   23
  Yamada 2011 \[[@B43-diagnostics-10-00460]\]                   Japan      13                   41    3    17   7    10   4
  Zucali 2010 \[[@B44-diagnostics-10-00460]\]                   Italy      8                    101   15   28   24   8    24

diagnostics-10-00460-t002_Table 2

###### 

Meta-analysis for the odds ratio of various immunohistochemical expressions between thymic carcinoma and thymoma.

  ------------------------------------------------------------------------------------------------------------------------------------
  Marker                  Number of\   Fixed Effect\                Heterogeneity Test\   Random Effect\               Egger's Test\
                          Subsets      \[95% CI\]                   \[*p*-Value\]         \[95% CI\]                   \[*p*-Value\]
  ----------------------- ------------ ---------------------------- --------------------- ---------------------------- ---------------
  Androgen receptor       3            0.362 \[0.120, 1.091\]       0.063                 0.740 \[0.065, 8.450\]       0.480

  beta-5t                 2            0.002 \[0.000, 0.030\]       0.564                 0.002 \[0.000, 0.030\]       \-

  beta-catenin            2            0.829 \[0.254, 2.704\]       0.022                 0.512 \[0.027, 9.722\]       \-

  Bcl-2                   4            2.461 \[1.043, 5.807\]       0.637                 2.461 \[1.043, 5.807\]       0.871

  Calretinin              1            19.429 \[2.218, 170.165\]    1.000                 19.429 \[2.218, 170.165\]    \-

  CD15                    2            4.139 \[1.413, 12.127\]      0.022                 2.263 \[0.130, 39.382\]      \-

  CD1a                    2            0.052 \[0.012, 0.223\]       0.073                 0.028 \[0.001, 0.623\]       \-

  CD205                   2            0.221 \[0.064, 0.759\]       0.019                 0.137 \[0.006, 3.046\]       \-

  CD5                     11           52.560 \[26.424, 104.547\]   0.972                 52.560 \[26.424, 104.547\]   0.034

  CEA                     2            45.273 \[5.567, 368.160\]    0.505                 45.273 \[5.567, 368.160\]    \-

  CK19                    2            0.061 \[0.016, 0.224\]       0.364                 0.061 \[0.016, 0.224\]       \-

  CK5/6                   4            0.191 \[0.080, 0.459\]       0.022                 0.294 \[0.054, 1.607\]       0.283

  c-Kit                   12           41.444 \[23.767, 72.267\]    0.771                 41.444 \[23.767, 72.267\]    0.024

  Cyclin D1               2            0.407 \[0.128, 1.298\]       0.006                 1.140 \[0.022, 58.476\]      \-

  E-cadherin              3            0.340 \[0.170, 0.680\]       0.001                 0.400 \[0.064, 2.516\]       0.167

  EGFR                    6            0.311 \[0.130, 0.741\]       0.014                 0.314 \[0.066, 1.493\]       0.964

  Estrogen receptor       1            0.319 \[0.012, 8.254\]       1.000                 0.319 \[0.012, 8.254\]       \-

  Glut-1                  4            11.607 \[3.003, 44.862\]     0.100                 15.187 \[2.082, 110.780\]    0.019

  HBME                    2            2.776 \[0.337, 22.853\]      0.088                 2.763 \[0.076, 100.781\]     \-

  IGF-1R                  6            10.216 \[5.611, 18.602\]     0.005                 9.465 \[2.869, 31.221\]      0.806

  Mesothelin              3            39.842 \[12.067, 131.542\]   0.876                 39.842 \[12.067, 131.542\]   0.386

  MOC31                   2            18.019 \[4.366, 75.113\]     0.874                 18.019 \[4.366, 75.113\]     \-

  MUC1                    3            44.866 \[11.273, 178.576\]   0.786                 44.866 \[11.273, 178.576\]   0.249

  p21                     2            10.270 \[2.862, 36.849\]     0.716                 10.270 \[2.862, 36.849\]     \-

  p53                     7            2.554 \[1.077, 6.055\]       0.029                 3.199 \[0.759, 13.481\]      0.487

  p63                     3            0.239 \[0.094, 0.610\]       0.013                 0.264 \[0.028, 2.482\]       0.924

  PAX8                    3            0.371 \[0.107, 1.288\]       0.065                 0.539 \[0.058, 4.989\]       0.505

  Progesterone receptor   2            1.681 \[0.170, 16.597\]      0.597                 1.681 \[0.170, 16.597\]      \-

  Survivin                2            1.251 \[0.358, 4.378\]       0.103                 0.733 \[0.056, 9.558\]       \-

  TdT                     2            0.015 \[0.003, 0.085\]       0.206                 0.014 \[0.001, 0.126\]       \-

  Thrombomodulin          1            0.449 \[0.023, 8.896\]       1.000                 0.449 \[0.023, 8.896\]       \-

  WT-1                    1            4.953 \[0.193, 127.130\]     1.000                 4.953 \[0.193, 127.130\]     \-
  ------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval.

diagnostics-10-00460-t003_Table 3

###### 

Meta-analysis for the odds ratio of various immunohistochemical expressions between thymic carcinoma and thymoma type B3.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker            Type               Number of Subsets        Fixed Effect\            Heterogeneity Test\      Random Effect\           Egger's Test\
                                                                \[95% CI\]               \[*p*-Value\]            \[95% CI\]               \[*p*-Value\]
  ----------------- ------------------ ------------------------ ------------------------ ------------------------ ------------------------ ---------------
  beta-5t           Thymic carcinoma   2                        0.031 \[0.004, 0.188\]   0.877                    0.031 \[0.004, 0.188\]   \-

  Thymoma type B3   2                  0.948 \[0.706, 0.993\]   0.511                    0.948 \[0.706, 0.993\]   \-                       

  beta-catenin      Thymic carcinoma   1                        0.750 \[0.448, 0.917\]   1.000                    0.750 \[0.448, 0.917\]   \-

  Thymoma type B3   1                  0.118 \[0.030, 0.368\]   1.000                    0.118 \[0.030, 0.368\]   \-                       

  CD1a              Thymic carcinoma   2                        0.127 \[0.036, 0.360\]   0.155                    0.096 \[0.012, 0.489\]   \-

  Thymoma type B3   2                  0.847 \[0.680, 0.935\]   0.682                    0.847 \[0.680, 0.935\]   \-                       

  CD205             Thymic carcinoma   2                        0.650 \[0.461, 0.801\]   0.371                    0.650 \[0.461, 0.801\]   \-

  Thymoma type B3   2                  0.958 \[0.757, 0.994\]   0.679                    0.958 \[0.757, 0.994\]   \-                       

  CD5               Thymic carcinoma   5                        0.722 \[0.610, 0.812\]   0.678                    0.722 \[0.610, 0.812\]   0.318

  Thymoma type B3   5                  0.100 \[0.039, 0.233\]   0.358                    0.096 \[0.035, 0.236\]   0.110                    

  CEA               Thymic carcinoma   1                        0.750 \[0.522, 0.892\]   1.000                    0.750 \[0.522, 0.892\]   \-

  Thymoma type B3   1                  0.029 \[0.002, 0.336\]   1.000                    0.029 \[0.002, 0.336\]   \-                       

  c-Kit             Thymic carcinoma   11                       0.688 \[0.607, 0.759\]   0.142                    0.692 \[0.591, 0.778\]   0.532

  Thymoma type B3   11                 0.099 \[0.060, 0.160\]   0.944                    0.099 \[0.060, 0.160\]   0.005                    

  Glut-1            Thymic carcinoma   4                        0.952 \[0.862, 0.985\]   0.827                    0.952 \[0.862, 0.985\]   0.017

  Thymoma type B3   4                  0.495 \[0.351, 0.640\]   0.105                    0.526 \[0.296, 0.745\]   0.621                    

  IGF-1R            Thymic carcinoma   5                        0.820 \[0.720, 0.890\]   0.580                    0.820 \[0.720, 0.890\]   0.147

  Thymoma type B3   5                  0.632 \[0.495, 0.751\]   0.179                    0.646 \[0.468, 0.791\]   0.573                    

  Mesothelin        Thymic carcinoma   1                        0.417 \[0.185, 0.692\]   1.000                    0.417 \[0.185, 0.692\]   \-

  Thymoma type B3   1                  0.028 \[0.002, 0.322\]   1.000                    0.028 \[0.002, 0.322\]   \-                       

  MOC31             Thymic carcinoma   1                        0.500 \[0.244, 0.756\]   1.000                    0.500 \[0.244, 0.756\]   \-

  Thymoma type B3   1                  0.118 \[0.030, 0.368\]   1.000                    0.118 \[0.030, 0.368\]   \-                       

  MUC1              Thymic carcinoma   3                        0.849 \[0.706, 0.930\]   0.140                    0.897 \[0.666, 0.975\]   0.034

  Thymoma type B3   3                  0.270 \[0.144, 0.449\]   0.051                    0.198 \[0.048, 0.549\]   0.462                    

  p21               Thymic carcinoma   1                        0.667 \[0.376, 0.869\]   1.000                    0.667 \[0.376, 0.869\]   \-

  Thymoma type B3   1                  0.118 \[0.030, 0.368\]   1.000                    0.118 \[0.030, 0.368\]   \-                       

  TdT               Thymic carcinoma   2                        0.070 \[0.018, 0.242\]   0.611                    0.070 \[0.018, 0.242\]   \-

  Thymoma type B3   2                  0.865 \[0.690, 0.949\]   0.336                    0.865 \[0.690, 0.949\]   \-                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval.
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###### 

Diagnostic test accuracy review of various immunohistochemical markers for differentiation between thymic carcinoma and thymoma type B3.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                     Marker    Included Studies         Sensitivity (%)\         Specificity (%)\             Diagnostic OR\                 AUC\
                                                        \[95% CI\]               \[95% CI\]                   \[95% CI\]                     on SROC
  ------------------ --------- ------------------------ ------------------------ ---------------------------- ------------------------------ ---------
  Thymic carcinoma   CD5       5                        0.731 \[0.622, 0.817\]   0.967 \[0.756, 0.996\]       23.936 \[7.693, 74.478\]       0.725

  c-kit              11        0.709 \[0.613, 0.790\]   0.925 \[0.873, 0.957\]   23.623 \[11.900, 46.894\]    0.910                          

  Glut-1             4         0.942 \[0.856, 0.978\]   0.464 \[0.225, 0.720\]   11.823 \[2.879, 48.549\]     0.916                          

  IGF-1R             3         0.875 \[0.760, 0.939\]   0.250 \[0.136, 0.415\]   4.050 \[1.087, 15.085\]      0.758                          

  MUC1               3         0.932 \[0.686, 0.988\]   0.847 \[0.505, 0.968\]   46.251 \[11.634, 183.877\]   0.921                          

  Thymoma type B3    beta-5t   2                        1.000 \[0.927, 1.000\]   1.000 \[0.942, 1.000\]       571.396 \[33.356, 9788.053\]   0.985

  CD1a               2         0.743 \[0.628, 0.832\]   0.952 \[0.504, 0.997\]   35.919 \[1.606, 803.371\]    0.871                          

  CD205              2         1.000 \[0.931, 1.000\]   0.335 \[0.165, 0.504\]   11.735 \[1.368, 100.632\]    0.785                          

  TdT                2         0.879 \[0.718, 0.954\]   0.933 \[0.769, 0.983\]   93.458 \[14.682, 594.912\]   0.958                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; OR, odds ratio; AUC, area under the curve; SROC, summary receiver operating characteristic.

[^1]: Jae-Han Jeong and Jung-Soo Pyo have contributed equally to this study.
